Andere Kunden interessierten sich auch für
![Roadmap to Prevent and Combat Drug-Resistant Tuberculosis]( "Roadmap to Prevent and Combat Drug-Resistant Tuberculosis")
Roadmap to Prevent and Combat Drug-Resistant Tuberculosis33,99 €![Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis]( "Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis")
Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis20,99 €![Tuberculosis - India is fighting for elimination: Weaker private sector in managing TB: Drug Resistant TB - a big challenge]( "Tuberculosis - India is fighting for elimination: Weaker private sector in managing TB: Drug Resistant TB - a big challenge")
Tuberculosis - India is fighting for elimination: Weaker private sector in managing TB: Drug Resistant TB - a big challenge35,99 €![Crisis Standards of Care]( "Crisis Standards of Care")
Crisis Standards of Care55,99 €![Guidance for Establishing Crisis Standards of Care for Use in Disaster Situations]( "Guidance for Establishing Crisis Standards of Care for Use in Disaster Situations")
Guidance for Establishing Crisis Standards of Care for Use in Disaster Situations47,99 €![Crisis Standards of Care]( "Crisis Standards of Care")
Crisis Standards of Care61,99 €![Leadership by Example]( "Leadership by Example")
Leadership by Example44,99 €
Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.